We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Morphic Holding Inc (MORF) USD0.0001

Sell:$50.00 Buy:$61.80 Change: $0.46 (0.80%)
Market closed |  Prices as at close on 22 October 2021 | Switch to live prices |
Change: $0.46 (0.80%)
Market closed |  Prices as at close on 22 October 2021 | Switch to live prices |
Change: $0.46 (0.80%)
Market closed |  Prices as at close on 22 October 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Morphic Holding, Inc. is a biopharmaceutical company. The Company is engaged in discovering and developing a pipeline of oral small molecule integrin therapeutics. Integrins are a target class with multiple approved injectable blockbuster drugs for the treatment of serious chronic diseases, including autoimmune, cardiovascular and metabolic diseases, fibrosis and cancer. The Company is advancing its pipeline, including its lead product candidate, MORF-057, an Alpha 4 and Beta 7-specific integrin inhibitor affecting inflammation, for the treatment of inflammatory bowel disease (IBD). It has also developed oral αvb6-specific integrin inhibitors including MORF-720 and MORF-627, for the treatment of fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). The Company is using its MInT Platform to advance a pipeline of preclinical programs across a variety of therapeutic areas.

Contact details

35 Gatehouse Dr # A2
United States
+1 (978) 7296480

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$2.08 billion
Shares in issue:
36.42 million
United States
US dollar

Key personnel

  • Gustav Christensen
    Independent Chairman of the Board
  • Praveen Tipirneni
    President, Chief Executive Officer, Director
  • Timothy Springer
    Founder, Independent Director
  • Marc Schegerin
    Chief Financial Officer, Chief Operating Officer
  • Robert Farrell
    Senior Vice President - Finance, Chief Accounting Officer
  • Bruce Rogers
    Chief Scientific Officer
  • William DeVaul
    General Counsel, Secretary
  • Peter Linde
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.